The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
USA001
Dallas, Texas, United States
Parts 1 and 2: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
Pharmacokinetics of brensocatib following a single dose in healthy participants will be assessed.
Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 7, 17 (Part 1), and Days 1 to 7, 12 to 18 (Part 2)
Parts 1 and 2: Number of Participants Who Experienced at Least One Adverse Event (AE)
Safety and tolerability of brensocatib when administered alone and in combination with rifampin/esomeprazole will be determined in healthy participants.
Time frame: Up to Day 31 (Part 1) and up to Day 26 (Part 2)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.